Abnormal polyamine metabolism is unique to the neuropathic forms of MPS: potential for biomarker development and insight into pathogenesis
Open Access
- 19 July 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (19) , 3837-3849
Abstract
The mucopolysaccharidoses (MPS) are rare genetic disorders marked by severe somatic and neurological symptoms. Development of treatments for the neurological manifestations of MPS has been hindered by the lack of objective measures of central nervous system disease burden. Identification of biomarkers for central nervous system disease in MPS patients would facilitate the evaluation of new agents in clinical trials. High throughput metabolite screening of cerebrospinal fluid (CSF) samples from a canine model of MPS I revealed a marked elevation of the polyamine, spermine, in affected animals, and gene therapy studies demonstrated that reduction of CSF spermine reflects correction of brain lesions in these animals. In humans, CSF spermine was elevated in neuropathic subtypes of MPS (MPS I, II, IIIA, IIIB), but not in subtypes in which cognitive function is preserved (MPS IVA, VI). In MPS I patients, elevated CSF spermine was restricted to patients with genotypes associated with CNS disease and was reduced following hematopoietic stem cell transplantation, which is the only therapy currently capable of improving cognitive outcomes. Additional studies in cultured neurons from MPS I mice showed that elevated spermine was essential for the abnormal neurite overgrowth exhibited by MPS neurons. These findings offer new insights into the pathogenesis of CNS disease in MPS patients, and support the use of spermine as a new biomarker to facilitate the development of next generation therapeutics for MPS.Keywords
Funding Information
- National Institute of Environmental Health Sciences (P30ES013508)
This publication has 40 references indexed in Scilit:
- Review of clinical presentation and diagnosis of mucopolysaccharidosis IVAMolecular Genetics and Metabolism, 2013
- MetaboAnalyst 2.0--a comprehensive server for metabolomic data analysisNucleic Acids Research, 2012
- Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB miceMetabolic Brain Disease, 2011
- Increased Synthesis of Spermidine as a Result of Upregulation of Arginase I Promotes Axonal Regeneration in Culture andIn VivoJournal of Neuroscience, 2009
- MetaboAnalyst: a web server for metabolomic data analysis and interpretationNucleic Acids Research, 2009
- Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIBMolecular and Cellular Neuroscience, 2009
- The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UKOrphanet Journal of Rare Diseases, 2008
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy imagesCytometry Part A, 2004
- Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sourcesBone Marrow Transplantation, 2003